In addition to acting as current President and Chief Executive Officer (CEO) of Zenith Epigenetics, Donald McCaffrey is the Co-Founder, President, & CEO of Resverlogix Corp. (TSX-RVX). He has over 35 years of business experience including 15 years of drug discovery & development. Donald has led Resverlogix through significant changes and achievements from its initial days as a private company to becoming a TSX listed company. He has personally raised over $300 million for research and clinical development in the areas of cardiovascular disease, diabetes mellitus, Alzheimer’s disease and other serious indications.
Donald’s expertise in corporate operations has attracted an international team of experts in research, development, and corporate affairs to Resverlogix. Under Donald’s guidance, Resverlogix was honored with multiple awards, the most prestigious being the 2008 World Economic Forum (WEF) Technology Pioneer award in Davos, Switzerland.